Immunomodulatory Potential of Escitalopram on C‐C Motif Chemokine Ligand 5 and Fibroblast Growth Factor 2 in Patients With Generalised Anxiety Disorder
In GAD patients, serum levels of CCL5 remained elevated and FGF2 increased significantly post-treatment with escitalopram. This suggests that escitalopram could exert a partial immunomodulatory effect on CCL5 and FGF2, thus modulating inflammation-driven mechanisms of GAD. Future research in larger populations and longer follow-ups is needed to further examine these findings.
Authors
- Sumita Halder (ORCID: https://orcid.org/0000-0001-5268-6444)
- Swathi Suresh
- Seema Garg (ORCID: https://orcid.org/0000-0003-0044-5977)
- Rachna Gupta (ORCID: https://orcid.org/0000-0002-3377-9626)
- Shruti Srivastava (ORCID: https://orcid.org/0000-0003-3472-7665)
Institutions
- University of Delhi (IN)
- University College of Medical Sciences (IN)
- Guru Teg Bahadur Hospital (IN)
Publication Details
- Journal
- Human Psychopharmacology Clinical and Experimental
- Published
- 2025-10-28
- DOI
- https://doi.org/10.1002/hup.70023
- Citations
- 1
- Primary Topic
- Tryptophan and brain disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.58